Alexion Pharmaceuticals, Inc. ALXN
We take great care to ensure that the data presented and summarized in this overview for ALEXION PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ALXN
Top Purchases
Top Sells
About ALXN
Insider Transactions at ALXN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 21
2021
|
John J Orloff EVP, Research & Development |
SELL
Sale (or disposition) back to the issuer
|
Direct |
146,511
-100.0%
|
-
|
|
Jul 21
2021
|
Ludwig Hantson CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
580,809
-98.46%
|
-
|
|
Jul 21
2021
|
Andreas Rummelt Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
28,109
-100.0%
|
-
|
|
Jul 21
2021
|
Francois Nader Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,921
-100.0%
|
-
|
|
Jul 21
2021
|
Indrani Lall Franchini EVP, Chief Compliance Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
116,075
-100.0%
|
-
|
|
Jul 21
2021
|
Daniel Bazarko SVP, Controller, CAO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
60,207
-100.0%
|
-
|
|
Jul 21
2021
|
Ellen Chiniara EVP & Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
116,850
-100.0%
|
-
|
|
Jul 21
2021
|
Brian Goff EVP & Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,832
-100.0%
|
-
|
|
Jul 21
2021
|
David R Brennan Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,873
-100.0%
|
-
|
|
Jul 21
2021
|
John T Mollen Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,336
-100.0%
|
-
|
|
Jul 21
2021
|
Tanisha Carino EVP & CCAO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
59,226
-100.0%
|
-
|
|
Jul 21
2021
|
Deborah Dunsire Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,629
-100.0%
|
-
|
|
Jul 21
2021
|
Judith A Reinsdorf Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,150
-100.0%
|
-
|
|
Jul 21
2021
|
Paul A Friedman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,840
-100.0%
|
-
|
|
Jul 21
2021
|
Aradhana Sarin EVP, CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
120,253
-100.0%
|
-
|
|
Jul 21
2021
|
Christopher J Coughlin Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
42,347
-100.0%
|
-
|
|
Jul 14
2021
|
Brian Goff EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,144
+18.26%
|
-
|
|
Jul 14
2021
|
Tanisha Carino EVP & CCAO |
BUY
Grant, award, or other acquisition
|
Direct |
25,813
+30.35%
|
-
|
|
Jul 14
2021
|
Ellen Chiniara EVP & Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,469
+21.13%
|
-
|
|
Jul 14
2021
|
John J Orloff EVP, Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
60,144
+18.76%
|
-
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders